NCT00512759View on ClinicalTrials.gov

Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study

PHASE4CompletedINTERVENTIONAL
Enrollment

781

Participants

Timeline

Start Date

December 10, 2007

Primary Completion Date

August 24, 2018

Study Completion Date

February 21, 2019

Conditions
Acute Heart Failure
Interventions
DRUG

Goal-directed preload and afterload decrement

Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).

Trial Locations (12)

4031

University Hospital Basel, Basel

5001

Kantonsspital Aarau, Aarau

6000

Kantonsspital Luzern, Lucerne

9007

Kantonsspital St. Gallen, Sankt Gallen

55131

University Hospital Mainz, Mainz

90419

Nuremberg Hospital, Nuremberg

04024-002

Hospital Sao Paolo, São Paulo

Unknown

5-th Multifunctional Hospital for Active Treatment, Sofia

"National Transport Hospital Tsar Boris III", Sofia

"University Hospital Tsaritsa Joanna-ISUL", Sofia

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT00512759 - Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study | Biotech Hunter | Biotech Hunter